INTRODUCTION
Twins occur at a rate of 25.9 per 1000 live births. Since 1980, the overall number of twin pregnancies has risen 47% and the twin birth rate by 37%. 1 This increase is believed in part to be related to the use of assisted reproductive technologies and the shift toward delayed childbearing. United States birth certificate data for 1996 reveals that in those with twin gestations the incidence of prematurity was 53%. The incidence of low birth weight for twins was also 53%, which is seven times higher than the overall low birth weight rate of 7.4%. 1 The presence of twins, in and of itself, is thus an established risk factor for preterm birth. 2 Indeed, multiple births have significant impact on perinatal morbidity and mortality.
Parenteral tocolysis has been shown to be successful in delaying delivery for 24 to 48 hours in patients presenting with preterm labor. 3, 4 The need for continued tocolysis to prevent recurrent preterm labor after initial stabilization has been a subject of debate. 5 ± 8 The clinical efficacy of maintaining tocolysis is often questioned due to lack of evidence that this practice can reduce the overall incidence of preterm birth. Tocolysis is often considered to be a failure if term gestation is not achieved. However, in women experiencing preterm labor, any additional gestational days gained with tocolysis should be deemed a success as evidenced by a reduction in neonatal morbidity and mortality with each gestational week gained. 9, 10 Terbutaline sulfate in oral form is often prescribed for maintenance tocolysis. The efficacy of oral terbutaline is influenced by patient compliance and the development of tachyphylaxis related to long-term, high-dose exposure. 11 The cardiovascular, renal, pulmonary, and metabolic effects of oral and parenteral terbutaline are considered to be dose-and route-dependent. 12 Studies of continuous subcutaneous terbutaline infusion therapy have suggested a low incidence of cardiovascular side effects, as well as efficacy in prolonging pregnancies between 5.4 and 9.2 weeks.
± 16
The subcutaneous infusion pump used for this method of delivery is individually programmed to deliver a continuous administration of low-dose terbutaline (basal rate) along with additional scheduled bolus doses that can be coordinated with peak times of uterine contractions.
The purpose of this investigation was to compare gestational days gained in a cohort of women with twin gestations receiving oral terbutaline for maintenance tocolysis after an episode of threatened preterm labor who then received continuous subcutaneous terbutaline after a subsequent episode of preterm labor.
OBJECTIVE:
To compare gestational days gained with oral versus subcutaneous terbutaline for maintenance tocolysis.
STUDY DESIGN:
In retrospective fashion 386 women enrolled in an outpatient preterm labor identification program met the following criteria: twin gestation, development of threatened preterm labor resulting in treatment with oral terbutaline, and subsequent recurrence of threatened preterm labor resulting in treatment with continuous subcutaneous terbutaline. The primary outcome was gestational days gained with oral terbutaline versus gain with continuous subcutaneous terbutaline.
RESULTS:
There were significantly more days gained during subcutaneous treatment than during oral treatment ( 34.0 19.8 versus 19.3 15.3 days ) . Thirtythree percent of desired prolongation was achieved with oral terbutaline, whereas 79% of desired prolongation was achieved with subcutaneous terbutaline ( p < 0.001 ) . Patients gained a mean of 53.4 21.4 days overall with outpatient tocolysis. The mean gestational age at delivery was 35.2 1.9 weeks.
CONCLUSION:
Continuous subcutaneous terbutaline was superior to oral terbutaline in prolonging gestation in women with twin gestations. 
MATERIALS AND METHODS
Subjects were identified from a database of women with high-risk pregnancies who were enrolled by their physician in a nationally available preterm-labor identification program. This outpatient program included patient education regarding the signs and symptoms of preterm labor, home uterine-activity monitoring, and telephonic nursing assessment of objective patient data and subjective symptoms. Between January 1992 and December 1997, prospectively collected demographics, pregnancy risk factors, uterine activity, subjective symptoms, and pregnancy outcome data were available for 4589 women with multiple gestations who received continuous subcutaneous terbutaline infusion at some time during their pregnancy. For this study, 386 women met the following inclusion criteria: (1) twin gestation, (2) no prophylactic tocolysis or diagnosis of preterm labor before enrollment into the program, (3) subsequent development of threatened preterm labor resulting in maintenance tocolysis with oral terbutaline, (4) recurrence of threatened preterm labor resulting in a change in terbutaline administration route to continuous subcutaneous infusion, and (5) no concomitant maintenance tocolysis during either treatment period. Threatened preterm labor was defined as an increase in uterine contractions above a physician-prescribed threshold (three to four contractions per hour) that led to a change in treatment protocol, which included hospitalization or a change in tocolytic medication or route of administration. Exclusions included 689 women with greater than twin gestation, 2389 with a preterm-labor diagnosis before enrollment, and 1125 patients receiving prophylactic tocolysis before enrollment or subcutaneous terbutaline therapy without prior exposure to oral terbutaline. At enrollment, informed consent was obtained for all participating patients.
The dose, frequency, and route of terbutaline (oral or subcutaneous infusion) were determined by the physician's prescription. Patient management including antenatal testing, additional medications, in-hospital stabilization, recommended activity level, and timing of delivery were at the discretion of each patient's attending physician.
At initiation of subcutaneous terbutaline therapy, the microinfusion pump (MiniMed Technologies, Sylmar, CA or Disetronics, Minneapolis, MN) was programmed to deliver a continuous basal rate and intermittent bolus doses as was prescribed by the patient's physician based on each patient's needs as determined by individual objective and subjective nursing assessments. Patients received individualized instruction on infusion pump use, including infusion initiation technique, site selection and care, syringe change, and emergency procedures, as well as the procedure for administering an unscheduled drug bolus if ordered by her physician.
In this retrospective cohort design each patient was used as her own control to assess individual response to change in medication route of delivery of terbutaline. The primary outcome variable was gestational days gained during each route of terbutaline administration. Elapsed time from start of terbutaline until threatened recurrent preterm labor occurred was analyzed for the oral terbutaline period, and compared to the elapsed time until preterm labor resulting in delivery, or discharge at term (36 weeks) for the subcutaneous terbutaline period. The pregnancy prolongation index was calculated to assess the level of treatment success for each route of tocolysis. Defined as the lag time between onset of treatment and discontinuation of treatment divided by the lag time between onset of treatment and 36 weeks, the PPI attempts to create an unbiased probability distribution for delivery weighted for gestational age at start of treatment. The PPI represents the percent of achieved pregnancy prolongation relative to the goal of therapy. 17 Other data collected for analysis included maternal demographics, pregnancy history and current pregnancy risk factors, maternal and neonatal outcomes, and antepartum hospital days. Uterine activity data collected 6 days before and 6 days after initiation of both oral and subcutaneous terbutaline was also analyzed.
Data were analyzed using McNemar's chi-square or Wilcoxon signed rank test statistics for paired samples, using Statistical Package for Social Sciences (SPSS) PC for Windows, version 7.0 (SPSS, Chicago, IL). All p-values presented are two-tailed and considered statistically significant if <0.05.
RESULTS
Demographic characteristics of the study population are described in Table 1 . The mean gestational age at enrollment into the preterm labor identification program was 25.03.5 weeks. Table 2 shows historical and current pregnancy risk factors at time of enrollment. The mean gestational age at initiation of oral terbutaline was 27.62.7 weeks with a starting mean dose of 18.78.8 mg/24 hr. One hundred seventy-six patients (46.2%) required changes (range 1±4) in the dosage or frequency of their oral terbutaline resulting in a mean dose of 24.410.7 mg/24 hr. The mean gestational age at initiation of continuous subcutaneous terbutaline infusion was 30.32.8 weeks at a starting mean dose of 3.31.0 mg/24 hr. The 24-hr dose was comprised of a mean continuous basal rate of 0.060.03 mg/hr, and a mean of 7.42.3 scheduled boluses of 0.250.02 mg. Two hundred thirty-three patients (60%) Pregnancy prolongation data are summarized in Figure 1 . Desired prolongation was calculated as the time (in days and weeks) from gestational age at start of treatment to 36 weeks. While receiving oral terbutaline women achieved a mean pregnancy prolongation of 19.315.3 vs. 34.019.8 days while receiving subcutaneous terbutaline ( p<0.001). The pregnancy prolongation index was applied to assess the level of treatment success for each administration route of terbutaline. Patients achieved significantly greater pregnancy prolongation on subcutaneous terbutaline (SQT) than on oral (PO) terbutaline. While receiving oral terbutaline women only achieved 33% (0.33.21) of desired pregnancy prolongation, compared with 79% (0.79.26) accomplishing desired prolongation while receiving subcutaneous therapy ( p<0.001). Overall, these pregnancies achieved a total of 20,609 days gained (mean 53.421.4 days per patient) with the combination of oral and subcutaneous terbutaline. 93.7% (19, 305) of these days were outpatient. One hundred fifty-four (39.9%) women had antepartum hospital days while receiving oral terbutaline, vs. 164 (42.5%) women with antepartum hospital days during subcutaneous terbutaline treatment ( p=0.510). The proportion of hospital days to tocolytic treatment days was equal for the oral and subcutaneous phases with women spending 6.3% of each period hospitalized. Only 15 patients (4%) in the study group were hospitalized for an extended period ( >14 days) while receiving oral and/or subcutaneous terbutaline.
Uterine activity for 6 days before and after oral terbutaline initiation, 6 days before and after change to the subcutaneous route, and for 6 days before delivery is illustrated in Figure 2 . This suggests a rise in mean uterine contractions per hour before each acute episode of preterm labor, with a stabilization of uterine activity the week following either initiation of oral, or change to subcutaneous terbutaline. Six days before initiation of oral terbutaline, women experienced a mean of 2.31.7 (median 2.0) uterine contractions per monitored hour, this increased to 4.43.3 (median 3.5) on the day before oral-therapy start. There again was a progressive increase in uterine activity per monitored hour in the 6 days before recurrence of preterm labor and initiation of subcutaneous therapy for a mean of 3.12.1 (median 3.0) at 6 days prior, to 4.83.2 (median 4.5) on the day before subcutaneous start.
Pregnancy outcome data are displayed on Table 3 . A total of 452 infants (58.5%) delivered at less than 36.0 weeks' gestation. A total of 473 infants (61.8%) were of low birth weight (less than 2500 gm). The reasons for delivery are presented on Table 4 . Tocolytic breakthrough and recurrent preterm labor resulting in delivery occurred in 104 women. Five women experienced the loss of one twin. There were two stillborn infants and three neonatal deaths, all of which occurred at gestational ages less than 35 weeks. All neonatal deaths occurred at less than 24 hours of age and were related to multiple congenital anomalies, hypoplastic lungs, or Trisomy-13. One intrauterine fetal death occurred in a pregnancy complicated with PIH. The other intrauterine death was in a fetus diagnosed with Downs Syndrome.
COMMENT
The purpose of this investigation was to compare gestational days gained by route of terbutaline administration (oral or subcutaneous infusion). We have shown that in women with twin gestations who experienced recurrent threatened preterm labor, pregnancy was prolonged 57% longer when terbutaline was administered through continuous subcutaneous infusion than when administered orally. This was achieved in spite of a six times lower daily dose of terbutaline when compared to oral administration. Overall, patients gained a mean of 7.6 weeks' gestation with oral and subcutaneous terbutaline. This gain is significantly greater than the 4-and 5-week gains achieved with placebo recently reported 18, 19 and is consistent with previous reports on women utilizing subcutaneous terbutaline therapy. Furthermore, we observed that uterine activity increases before the onset of preterm labor in women with twin gestations. This is supportive of the works of Nageotte et al., 20 Katz et al., 21 and Garite et al., 22 who showed a surge, or crescendo, of uterine activity 3 days before the onset of spontaneous labor.
In the literature there are other reported experiences with continuous subcutaneous terbutaline infusion. Lam et al., 14 reported on nine patients successfully treated with continuous subcutaneous terbutaline after failed oral tocolysis. Pregnancies were prolonged an average of 9.2 weeks with subcutaneous therapy. More recently, Lam et al., 23 reported on 256 women with singleton gestations comparing pregnancy prolongation with oral versus subcutaneous terbutaline in patients with recurrent preterm labor. Women achieved an average of 2.7 weeks with oral terbutaline versus 4.4 weeks with subcutaneous terbutaline. Combined mean pregnancy prolongation with progressive tocolysis was 7.14 weeks.
Allbert et al., 24 in a matched case design, compared 32 patients receiving continuous subcutaneous terbutaline infusion to patients receiving oral therapy. He concluded that the terbutaline pump appeared to be more successful in prolonging gestation than oral therapy. Utilizing the pregnancy prolongation index, women receiving oral therapy achieved 72% desired prolongation compared to 86% desired prolongation for subcutaneous therapy. A descriptive analysis of 992 very high-risk patients, including 206 twin pregnancies, receiving continuous subcutaneous terbutaline infusion, also by Allbert et al., 15 showed a mean pregnancy prolongation of 3823 days. Elliott et al., 25 reported success in utilizing prophylactic subcutaneous terbutaline infusion in 21 patients with high-order multiple gestations. Moise et al., 26 reported on 13 patients given continuous subcutaneous terbutaline using pump after failure of other tocolytic regimens. Though he considered his findings to reflect only limited success, patients gained an average of 35 days. Adkins et al., 16 reported on 51 patients, including four with twins, prescribed continuous subcutaneous terbutaline as treatment for their first episode of preterm labor. He reported a success rate of 98%, with pregnancies prolonged an average of 6.6 weeks.
Wenstrom et al., 18 randomized 42 women with singleton and twin pregnancies, who were stable on parenteral tocolysis, into three groups: terbutaline pump, saline pump, or oral terbutaline. There were no differences noted between the groups in birth outcomes. It should be noted that patients received only a mean of 1.52.4 scheduled boluses per day in the terbutaline pump group, which is considerably less than standard practice, and considerably less than patients in our present study who received a mean of 7.42.3 boluses. In addition, all patients were given a basal rate of 0.05 mg/hr, which was not titrated to level of uterine irritability exhibited. Most importantly, crossover between groups occurred as patients who failed one route of therapy were switched to another group. Fifty percent of the patients in the placebo group ultimately received either continuous subcutaneous terbutaline, or intravenous tocolytics. Based on intent to treat analysis, this study concluded that terbutaline by pump, saline by pump, and oral terbutaline were equally efficacious. The authors reported no serious complications related to terbutaline pump therapy.
Most recently, Guinn et al., 19 randomized 52 women with singleton gestation to either terbutaline or placebo through subcutaneous infusion. Overall, there was only a 1-day difference in pregnancy prolongation between the groups with the terbutaline 
Lam et al.
Gestational Gain, Terbutaline, and Twin Gestations group achieving a 28.822.0-day prolongation. It is not specified in the study if treatment was initiated at the first episode of preterm labor, or at a recurrent episode. Patients did not receive daily nursing contact or home uterine-activity monitoring as is generally prescribed in obstetric practice for women receiving continuous subcutaneous terbutaline infusion. It must be noted that the cervix in 50% of the patients in this study was 3 cm or more dilated and at least 50% effaced, at start. Patients were enrolled at a mean of 31 weeks, which made the predicted 6-week prolongation impossible, and were not treated for recurrent preterm labor occurring after 34 weeks. Also, dosing was not individualized or titrated to uterine activity, all women received a standard basal rate of 0.05 mg/hr and five scheduled boluses. The standard bolus schedule allowed for a 7-hour lapse during the nighttime hours, a period where there is a likelihood of increased uterine activity. 27 This current study was not designed to determine the overall efficacy or safety of maintenance tocolysis and did not compare to a control group of patients who did not receive tocolysis. While the debate over tocolytic efficacy persists, many physicians will continue to prescribe maintenance tocolysis. Our goal was to analyze two routes of terbutaline delivery, oral and subcutaneous, and compare overall time gained in utero for each treatment. As such, we found that in women with twin gestations who received terbutaline orally, then subcutaneously, greater pregnancy prolongation was achieved with subcutaneous administration.
